PRMA Insights: The Roadmap to Pricing and Reimbursement Success

The metastatic breast cancer report delivers

Use this report to gain an understanding of the following issues in the pricing and reimbursement of metastatic breast cancer in the major markets:

• an overview of MBC, with a focus on the key issues shaping the market access landscape
  
• a comprehensive review of MBC products, regulatory nominations, key supporting data packages and clinical guidelines
• the prices achieved for current products and their reimbursement status in each country
  
• how payors have critically evaluated the data packages for existing MBC products, including chemotherapies, targeted therapies and aromatase inhibitors
  
• an in-depth critical review of over 30 P&R and HTA assessments in MBC in the major markets
  
• the value propositions and arguments manufacturers have submitted for their products
  
• a review of the relevant risk-sharing agreements for products indicated for MBC
  
• the implications surrounding the choice of comparators and endpoints included in clinical trials for P&R assessments
  
• the key learnings and market access insights for developing a new product in MBC
  
• a review of the epidemiology and burden of MBC, with insights into evidence gaps and the impact on your health outcomes strategy
  
• a review of the existing instruments used to measure health-related quality of life (HRQoL) in MBC, opportunities for the inclusion of HRQoL data in your label, and how this could differentiate your product and impact P&R 
  
  

Find out more about the metastatic breast cancer report:

The report delivers         Scope of the report        Authors of the report